Vigil Neuroscience (NASDAQ:VIGL) Downgraded to "Neutral" Rating by HC Wainwright

HC Wainwright lowered shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) from a buy rating to a neutral rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. HC Wainwright currently has $8.00 target price on the stock, down from their previous target price of $14.00. HC Wainwright also issued estimates for Vigil Neuroscience's FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.63 EPS.

Several other research analysts have also commented on VIGL. Guggenheim set a $8.00 price objective on Vigil Neuroscience and gave the company a "neutral" rating in a research report on Thursday, May 22nd. JMP Securities reaffirmed a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Wedbush lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating and dropped their target price for the stock from $13.00 to $8.00 in a research report on Thursday, May 22nd. William Blair lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Citizens Jmp lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $10.80.

Vigil Neuroscience Price Performance

NASDAQ:VIGL remained flat at $7.88 during mid-day trading on Tuesday. The company's stock had a trading volume of 1,210,695 shares, compared to its average volume of 657,423. The business has a 50-day simple moving average of $2.79 and a two-hundred day simple moving average of $2.45. Vigil Neuroscience has a one year low of $1.31 and a one year high of $7.95. The company has a market capitalization of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, sell-side analysts forecast that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Trading of Vigil Neuroscience

Hedge funds and other institutional investors have recently bought and sold shares of the company. abrdn plc increased its holdings in Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after buying an additional 293,461 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after buying an additional 8,358 shares during the last quarter. Barclays PLC increased its holdings in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares during the last quarter. Blair William & Co. IL bought a new stake in Vigil Neuroscience in the fourth quarter valued at about $551,000. Finally, 683 Capital Management LLC increased its holdings in Vigil Neuroscience by 14.8% in the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock valued at $2,380,000 after buying an additional 180,420 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.